Loading…
Evaxion A/S is projected to rise to $3.08 by 2027, a +5% move from its current price of $2.95. EVAX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/5/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 6 | $2.87 | $2.95 | $3.03 | -0.03% |
| Aug 7 | $2.83 | $2.95 | $3.07 | -0.06% |
| Aug 8 | $2.81 | $2.95 | $3.09 | -0.09% |
| Aug 9 | $2.79 | $2.95 | $3.11 | -0.11% |
| Aug 10 | $2.77 | $2.95 | $3.13 | -0.14% |
| Aug 11 | $2.75 | $2.94 | $3.15 | -0.17% |
| Aug 12 | $2.74 | $2.94 | $3.17 | -0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.74 | $2.94 | $3.17 | -0.20% |
| Week 2 | $2.65 | $2.94 | $3.26 | -0.40% |
| Week 3 | $2.58 | $2.93 | $3.33 | -0.59% |
| Week 4 | $2.53 | $2.93 | $3.39 | -0.79% |
| Week 5 | $2.48 | $2.92 | $3.44 | -0.99% |
| Week 6 | $2.43 | $2.92 | $3.49 | -1.18% |
| Week 7 | $2.40 | $2.91 | $3.53 | -1.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Evaxion A/S is in the Healthcare sector and is described as a clinical-stage biotech company that develops artificial intelligence-powered immunology vaccines. It develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, a DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S.
aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
EVAX is Evaxion A/S, a healthcare stock (symbol EVAX) with a current price of $2.94 and a market capitalization of $24.52M. It holds a relatively low market-cap position, ranking 4519. The forecasted price path suggests modest moves near the current level in 2026, with progressively stronger upside into the late 2020s and beyond.
By 2040 the average forecast is $6.21 and 2050 the average is $8.69, with a max of $11.00 in 2040 and $16.97 in 2050, indicating meaningful upside from today’s price. These figures imply a long-run bullish potential, though they are estimates and not guarantees. The current context remains sensitive to broader biotech risk and volatility.
A major floor 16.7% below — a decisive break under it would weaken the trend.
The nearest floor, 5.4% below — buyers have tended to step in here.
The nearest ceiling, 15.6% above — a clean break opens room to run.
A major ceiling 54.9% above — clearing it would confirm fresh momentum.
Key EVAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EVAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.88 | Buy | $2.92 | Buy |
| MA 10 | $2.90 | Buy | $2.92 | Buy |
| MA 20 | $2.98 | Sell | $3.00 | Sell |
| MA 50 | $3.31 | Sell | $3.27 | Sell |
| MA 100 | $3.69 | Sell | $3.55 | Sell |
| MA 200 | $4.24 | Sell | $3.98 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.18 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 32.26 | Neutral |
| Williams %R (14) | -15.72 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 3.07 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 84.28 | Sell |
| TRIX (15) | -0.64 | Sell |
| Awesome (5,34) | -0.21 | Sell |
| Ultimate (7,14,28) | 57.65 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 2.91 | Buy |
| ADX (14) | 21.26 | Sell |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is NEUTRAL with RSI(14) at 40. The stock trades below the 50-day moving average of $3.60 and far below the 200-day moving average of $4.47, suggesting near-term weakness relative to longer-term momentum. Support is placed at $2.94 and resistance at $3.79, with a 30-day range of $2.39 to $3.62.
The stock exhibits high volatility, evidenced by an annualized volatility of 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.79 | $2.95 | $3.74 | 0% | Neutral | |
| $2.46 | $3.08 | $4.09 | +5% | Neutral | |
| $2.52 | $3.25 | $4.49 | +10% | Neutral | |
| $2.31 | $3.05 | $4.34 | +4% | Neutral | |
| $2.28 | $3.08 | $4.48 | +4% | Neutral | |
| $2.53 | $3.48 | $5.19 | +18% | Neutral | |
| $2.93 | $4.11 | $6.25 | +39% | Bullish | |
| $3.08 | $4.39 | $6.79 | +49% | Bullish | |
| $2.97 | $4.29 | $6.74 | +46% | Bullish | |
| $3.04 | $4.47 | $7.13 | +52% | Bullish | |
| $4.04 | $6.37 | $10.81 | +116% | Bullish | |
| $5.29 | $9.38 | $17.44 | +218% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.79 | $2.95 | $3.60 | +0.00% |
| September 2026 | $2.48 | $2.93 | $3.56 | -0.73% |
| October 2026 | $2.41 | $2.87 | $3.53 | -1.84% |
| November 2026 | $2.46 | $2.95 | $3.66 | +2.68% |
| December 2026 | $2.48 | $2.99 | $3.74 | +1.22% |
Click any year to see its month-by-month EVAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The EVAX price prediction for 2026 points to an average of $2.95 (low $2.79, high $3.74) — a potential gain of 0% on today's $2.95. A consolidation phase looks the most probable path here.
In 2027, EVAX is projected to trade between $2.46 and $4.09, averaging $3.08 — a potential gain of +5% from today's $2.95. That is up +5% on the projected 2026 average. Price action looks broadly range-bound.
Evaxion A/S's 2028 outlook centres on $3.25, within a $2.52 to $4.49 range. That is up +6% on the projected 2027 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, EVAX could reach as high as $4.34, with a base case around $3.05 and support toward $2.31 — roughly +4% from $2.95. Price action looks broadly range-bound.
Expect EVAX to range from $2.28 to $4.48 through 2030. The $3.08 average target implies a +4% move from current prices. That is up +1% on the projected 2029 average. A consolidation phase looks the most probable path here.
The EVAX price prediction for 2031 points to an average of $3.48 (low $2.53, high $5.19) — a potential gain of +18% on today's $2.95. Price action looks broadly range-bound.
In 2032, EVAX is projected to trade between $2.93 and $6.25, averaging $4.11 — a potential gain of +39% from today's $2.95. That is up +18% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Evaxion A/S's 2033 outlook centres on $4.39, within a $3.08 to $6.79 range. That is up +7% on the projected 2032 average. That marks a +49% change versus current levels. Momentum favours further upside here.
By 2034, EVAX could reach as high as $6.74, with a base case around $4.29 and support toward $2.97 — roughly +46% from $2.95. Buyers look set to stay in control over this stretch.
Expect EVAX to range from $3.04 to $7.13 through 2035. The $4.47 average target implies a +52% move from current prices. That is up +4% on the projected 2034 average. Momentum favours further upside here.
The EVAX price prediction for 2040 points to an average of $6.37 (low $4.04, high $10.81) — a potential gain of +116% on today's $2.95. Buyers look set to stay in control over this stretch.
In 2050, EVAX is projected to trade between $5.29 and $17.44, averaging $9.38 — a potential gain of +218% from today's $2.95. That is up +47% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in EVAX today (≈ 338.983051 EVAX) could be worth
$3,179.05
+$2,179.05 (+218%) by 2050 · US Dollar
Based on the average projected EVAX price of $9.38 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EVAXwould be worth at today's price.
$1,000 invested in EVAX on Aug 5, 2025 (≈ 373.134319 EVAX) would be worth
$1,100.75
+$100.75 (+10.1%) today · 1.10× · US Dollar
Based on a EVAX entry price of $2.68 vs. today's $2.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.84 | $1,038.73 | +3.9% |
| 1 month ago | $3.38 | $872.78 | -12.7% |
| 3 months ago | $4.07 | $724.82 | -27.5% |
| 6 months ago | $3.36 | $877.98 | -12.2% |
| 1 year ago | $2.68 | $1,100.75 | +10.1% |
| All time (5.0y) ago | $297 | $9.93 | -99.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EVAX forecast.
Our base-case forecast reaches $5.90 around 2040.
Implied market cap at $5.90: $49.21M
Over the multi-year horizon, the forecast turns increasingly bullish from 2032 onward. The 2030 average price is $2.96 with a min of $2.14 and a max of $4.44, and a forecasted ROI of 0.8. From 2032 through 2035, the model exhibits bullish sentiment, with the 2032–2035 averages ranging up to $3.95, $4.30, $4.24 and $4.25 respectively and maxes up to $6.19, $6.87, $6.90 and $7.02, with ROIs of 34.4%, 46.2%, 44.3% and 44.5%.
The outlook strengthens into 2040, where the average price is $6.21 and the max is $11.00, yielding a 111.3% ROI. By 2050, the forecast shows an average of $8.69 with a max of $16.97 and an ROI of 195.5%. Overall, the path suggests meaningful upside potential in the distant horizon, but the early years show mixed returns and the forecast remains an estimate, not a guarantee.
The figure set also reflects the stock’s high volatility risk, consistent with a small-cap biotech.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.96, with a min of $2.14 and a max of $4.44, and a forecasted ROI of 0.8. The sentiment is NEUTRAL.
The forecast exhibits a mix of years with NEUTRAL sentiment in the near term and BULLISH sentiment from 2032 onward. Notable ROIs are 0.8% in 2030, 111.3% in 2040, and 195.5% in 2050, with the max price reaching $11.00 in 2040 and $16.97 in 2050. The stock remains a small-cap with high volatility (60%), so these are estimates, not guarantees.
Yes, according to the forecast the max price pathway reaches $11.00 in 2040 and $16.97 in 2050, which means a $10 level is within the modeled upside by the mid-to-late 2040s. These figures are not guaranteed.
For 2026 the average price is forecast at $2.94, with a min of $2.91 and a max of $3.74; the sentiment is NEUTRAL.
The current price is $2.94 and the market cap is $24.52M.
Evaxion A/S Community Discussion
0Share your Evaxion A/S price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.